2. Market Segmentation
Healthcare
Sector
Pharmaceutical
Biotechnology
Clinical Diagnostics
Medical Devices
Medical Imaging
Patient Monitoring
Remote Patient Monitoring
mHealth
General Healthcare IT
Telemedicine
MedTech
Life
Science
Connected
Health
• Chronic diseases (diabetes and cancer) and infectious diseases will continue driving demand
for newer, better and targeted therapeutics;
• Innovative vaccine products, diagnostics and early detection of HPV, HIV, cancers,
Alzheimer’s decease and genetic deceases are strongly demanded;
• Molecular diagnostics, point-of-care testing and immunoassays are the fastest-growing areas;
• Dug and diagnostic co-development will accelerate M&A.
• Roche has dominated the self monitoring of
blood glucose (SMBG) sub-segment due to
its innovative products;
• The growth in capital equipment such as CT
and MRI scanners is driven by the
increasing number private hospital projects
(greenfield);
• Compared to the Western countries,
Cardiac rhythm management is a less
penetrated market in the Asia-Pacific area;
• Singapore reduced regulatory requirement
for Class A device dealer licensing and
provisioned for faster access and lower
regulatory fees for Class C and D medical
devices, which is expected to be replicated
in Malaysia;
• Electronic Medical Records (EMR) &
Electronic Health Records (EHR);
• Personalisation of Devices and Sensors for
Monitoring Physiological Parameters;
• Professional Solutions for Smartphones and
Personal Devices Assistants to Facilitate
Healthcare Mobility.
Source: Frost & Sullivan, 2013 APAC Healthcare Outlook, March 2014: Potential market to focus for IMRE
3. Market Revenue for 2012
$64.78 B
CAGR for 2012 ~ 2016
10.2%
Market Size for 2016
$95.67 B
Degree of Technical
Change (scale of 1 to 10,
Low to High)
7.5
Base Year Market Growth
Rate
7.2%
Key Change
Increased Intelligence &
Diagnostics
Top 3 Vertical End Users
Process Control,
Automotive, Medical
Average Product
Development Period
2 years
Global Sensor Market Dynamics
Huge Market Size
Sensor End-User
Market Analysis (2012)
Chemicals & Petro.
10.8%
Medical
9.9%
Process Control
7.7%
O&G
5.9%
Automotive
10.8%
Sensor Product Market
Analysis (2012)
Biosensors
13.2%
Flow Sensors
10.1%
Pressure
9.0%
Level Sensors
7.7%
Temperature
6.9%
Image Sensor
7.0%
Gas Sensors
4.2%
Source: Frost & Sullivan, Global Sensor Outlook 2013, June 2013
4. High Growth Rate of Biosensor Market
CAGR = 11.7% for 2012 - 2016
Biosensors
Vertical
Market
Market
Size
2012
($ Million)
Growth
Potential
Market
Size
2016
($ Million)
Research
Laboratory
1,005.5 Medium 1,539.1
Home
Diagnostics
1,790.3 High 2,919.0
Point of Care 4,259.4 High 6,469.8
Process
Industries
606.3 Medium 951.0
Environment 1,208.3 High 2,065.1
Biodefense 258.2 High 477.1
Total 9,128.4 High 14,421.2
Source: Frost & Sullivan, Global Sensor Outlook 2013, June 2013
Biosensors
Process
Industry
Defense
Environmental
Monitoring
Agriculture &
Food Safety
Pharmacology
Medicine
• High risk of diabetes and obesity;
• Rising incidence of chronic disease like heart
disease, stroke, cancer, chronic respiratory diseases,
tuberculosis etc;
• High concern of food safety.
Healthcare
5. Drivers:
• Development of nanotechnology;
• Multiple application;
• High demand of in-line monitoring.
Constraints
• Low technology transfer rate from lab to
commercial application;
• Vulnerable biomolecules are sensitive
to harsh environments;
• High R&D expenses (ave. $25 -30
million).
Nitto Denko Asia Technical
Centre (NAT)
Sensitive Element
Value Chain of Biosensor Development Process
Source: Kirsch, Jeffrey (2013) “Biosensor Technology: recent advances in threat
agent detection and medicine”, Chem. Soc. Rov.,42, pp.8733
IMREIBN Nitto
6. Closed-Loop of Biosensor Development
Nanomedicine
Nanobiotechnology
Nanomachinary
Nanodevices
Gas Sensing
Polymer Sensing
Biological Sensing
……
NEMS*
To detect atom(s)
To detect biological molecules
(e.g. protein)
Nanomaterials:
CNT, NP, NW
Biological
Recognition
Interface
Integrated with
MEMS
A hypothetical approach to developing biosensors for medical application.
*NEMS: nano-electromechanical system
7. IMRE Staff Designation Capability Group
Dr. Wang, Zhijuan Scientist I
Synthesis & Integration
Dr. Li, Jun Senior Scientist III
Dr. Zheng, Yuangang Scientist III
Dr. Liu, Rongrong Scientist I
Dr. O'Shea, Sean Principal Scientist I
Analysis &
Characterization
Ms. Khin Moh Moh Aung Senior Specialist I
Dr. Su, Xiaodi Senior Scientist II
Dr. Zhou, Xiaodong (Donna) Senior Scientist I
Ms. Zhang, Nan Senior Specialist I
Ms. Kanjanawarut, Roejarek Specialist II
Dr. Free, Paul Francis Scientist I
Dr. Tan, Yennee Scientist III
Research Staff of IMRE in
Biosensors-Related Area
Glucose
31.6%
Cardiac Biomarkers
7.4%
Infectious Disease
5.8%
Toxicity
8.8%
Biosensor End-User Application (2012)
Source: Frost & Sullivan, Global Sensor Outlook 2013, June 2013
8. 0 625 1250 1875 2500
Carbon Nanotube (CNT)
Nanoparticles (NP)
Quantum Dot (QD)
Graphene
Chitosan
Dendrimer
Lipid / Liposome
Nanofiber
No. of Publication
21%
36%8%
16%
9%
2%
6%
2%
14%
39%
16%
20%
1%1%
4%
5%
Carbon Nanotube (CNT) Nanoparticle
Quantum Dot Graphene
Chitosan Dendrimer
Lipid / Liposome Nanofiber
Research Publication of IMRE on
Biosensors
• Title + Key word + Abstract: (biosensor OR nanosensor)
AND nanomaterials
• Year: 2010 - 2014
• Database: Scopus
IMRE
Worldwide
9. Research Publication of IMRE on
Biosensors
45%
25%
16%
5%
4%
3% 2%
Nanyang Technological University
National University of Singapore
Institute of Microelectronics
Institute of Materials Research and Engineering
Institute of Bioengineering and Nanotechnology
Yong Look Lin School of Medicine
Singapore INstitute of Manufacturing Technology
Collaborative Publication of IMRE on Biosensors (2010-2014)
NTU
NUS
IME
54%
7%
7%
7%
7%
7%
4%
4% 4%
Singapore Austria
China India
Thailand US
Germany New Zealand
Research Publication on Biosensors in Singapore (2010-2014)
SG
AT
CN
IN
TH
US
10. Summary
1.Medical devices, medical imaging, biotechnology and clinical
diagnostics can be the research focus for IMRE to make its
impact on healthcare sector;
2.There’s a great market for sensors in the medical application,
while biosensors have the largest market revenue.
3.Biosensors have high growth potential in research laboratory,
home diagnostics and point-of-care of healthcare sector.
4.NAT has demonstrated a successful collaborative mechanism
between IMRE and Nitto Denko in terms of the value chain of
biosensor development process.
11. 4.A closed-loop approach has been proposed in the development of
NEMS-based bionanosensors for IMRE in order to strengthen
IMRE’s impact on the R&D value chain.
5. The statistic result of IMRE’s research publication shows that
IMRE shares the same research interest with global statistics in
terms of nanomaterials research for biosensors application.
6.IMRE is suggested to seek more collaboration with NTU to rely on
its research strength in biosensors in the local context as well as
more and broader alliance with overseas institutes.
7.A further study on the patent of biosensors with benchmarking
global peers is expected to position IMRE’s capability in the
technology transfer map of this area.
Summary
